Perseus Proteomics Inc. (4882) Cash flow
Market cap
¥3.3B
P/E ratio
Perseus Proteomics develops high-performance antibodies for cancer treatment and drug discovery using proprietary technology from the University of Tokyo.
| 2019/03 | 2020/03 | 2021/03 | 2022/03 | 2023/03 | 2024/03 | 2025/03 | |
| Depreciation & amortization | 1 | 0 | 0 | 3 | 6 | 3 | 3 |
| Cash from operations | -330 | -609 | -423 | -477 | -564 | -834 | -719 |
| Capital expenditures | -15 | -3 | -3 | -34 | -164 | -143 | -75 |
| Cash from investing | -16 | -3 | -3 | -34 | -213 | -150 | -75 |
| Repurchases of common stock | - | - | - | - | -0 | -0 | - |
| Cash from financing | - | - | 1,011 | 2,648 | -0 | 64 | 923 |
| Free cash flow | |||||||
| FCF margin (%) |